Novastage Pharmaceuticals, Ltd.
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Brain Health
Novastage is a world leader in transdermal patches that have superior safety, efficacy and compliance over oral and injectable forms. The founders have previously developed 14 patch products in the US. Novastage has an advanced R&D center and a commercial plant that meets NMPA, FDA and EMA GMP requirements.
Novastage has a pipeline of 16 patch products. The first 4 products are:
*A 7-day risperidone patch has superior safety, efficacy and compliance over oral risperidone tablets and injectables and many other existing molecules for schizophrenia. US FDA has approved its IND application
*A 7 day contraceptive patch has 99% efficacy in contraception. Its overall efficacy is higher than oral tablets. Pilot BE passed
*An estradiol patch for the post menopause diseases bypasses hepatic first-pass metabolism, thereby offering cardiovascular benefits—such as a reduced risk of thrombosis and stroke relative to oral tablets
*Rotigotine patch for Parkinson’s disease is superior in compliance
Company HQ City:
Shenzhen
Company HQ State:
Guangdong province
Company HQ Country:
China
Year Founded:
2019
Lead Product in Development:
*A weekly risperidone patch has superior safety (especially lower EPS), efficacy and compliance over oral risperidone tablets and injectables and many other existing molecules for schizophrenia. US FDA has approved its IND application.
*A weekly contraceptive patch has 99% efficacy in contraception. Its overall efficacy is higher than oral tablets.
*A Twice a week Estradiol patch for the post menopause diseases bypasses hepatic first-pass metabolism, thereby offering cardiovascular benefits—such as a reduced risk of thrombosis and stroke relative to oral tablets
*Rotigotine patch for Parkinson’s disease is superior in compliance.
CEO
John Jianshneg Tang
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
Four (4) products
When you expect your next catalyst update?
Feb 2027.
What is your next catalyst (value inflection) update?
Risperidone patch Phase 1 Part1 study by February 2027 ；
2 Product submissions accepted by US FDA by Dec 2027;
We will achieve $ 100 million USD in 3 years， $500 millions in 5 years and $1.1 billion sales in 7 years.;
We plan to IPO in 2030 with Market value of $720 million.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}